{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:26:24Z","timestamp":1789453584665,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>There is limited evidence to support the currently suggested lamotrigine (LTG) therapeutic reference range of 2.5\u201315 mg\/L for the treatment of seizures. The objective of this study was to evaluate the association of LTG plasma concentrations with the efficacy and toxicity of the treatment in patients with epilepsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients whose LTG plasma concentration was measured between January 2013 and February 2022 were included. Efficacy was defined as seizure freedom for at least 6 months around the time of measured LTG concentration. Toxicity was defined as any LTG-related adverse drug effect documented in each patient's health record or when the reason for measuring the LTG concentration was toxicity. In addition, the dose\u2013concentration relationship of LTG was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 549 concentrations from 259 patients with epilepsy were included. The most common reasons for therapeutic drug monitoring were suspected inefficacy (39%) and pregnancy (21%). The LTG plasma concentration was not associated with efficacy (adjusted odds ratio = 0.94; 95% confidence interval, 0.85\u20131.04). The LTG plasma concentration was positively associated with the incidence of toxicity after adjusting for age, sex, and number of antiepileptic drugs (odds ratio = 1.11; 95% confidence interval, 1.04\u20131.19). The daily dose had a significant linear correlation with the LTG plasma concentration (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The LTG plasma concentration was associated with toxicity, whereas no association with efficacy was found. A reference range of 2.5\u201310 mg\/L may be considered to decrease the risk of toxicity while maintaining similar efficacy. Therapeutic drug monitoring may be useful when LTG-related toxicity is suspected and in cases of pharmacokinetic changes (eg, pregnancy and concomitant use of interacting drugs) that can influence the LTG plasma concentration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001205","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T21:01:23Z","timestamp":1713819683000},"page":"642-648","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Association of Lamotrigine Plasma Concentrations With Efficacy and Toxicity in Patients With Epilepsy: A Retrospective Study"],"prefix":"10.1097","volume":"46","author":[{"given":"Ze-Ning","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Nuland","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bogn\u00e0r","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans S. S.","family":"Leijten","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim C. M.","family":"van der Elst","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"17562864211037430","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7812\/TPP\/20.183","article-title":"Effectiveness at 24 Months of single-source generic carbamazepine, lamotrigine, or levetiracetam in newly diagnosed focal epilepsy","volume":"25","author":"Gurbani","year":"2020","journal-title":"Perm J"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"106408","DOI":"10.1016\/j.eplepsyres.2020.106408","article-title":"Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: an observational study in the real world","volume":"166","author":"Li","year":"2020","journal-title":"Epilepsy Res"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.12.008","article-title":"Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy","volume":"55","author":"Lee","year":"2018","journal-title":"Seizure"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40262-019-00845-2","article-title":"Therapeutic drug monitoring of antiepileptic drugs in women with epilepsy before, during, and after pregnancy","volume":"59","author":"Arfman","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/FTD.0000000000000433","article-title":"Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes of adult patients","volume":"39","author":"Grundmann","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1996.tb00605.x","article-title":"Concentration--effect and concentration--toxicity relations with lamotrigine: a prospective study","volume":"37","author":"Kilpatrick","year":"1996","journal-title":"Epilepsia"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1059-1311(96)80063-X","article-title":"Combination vigabatrin and lamotrigine therapy for intractable epilepsy","volume":"5","author":"Schapel","year":"1996","journal-title":"Seizure"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/j.1950-6945.2002.tb00436.x","article-title":"Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels","volume":"4","author":"Froscher","year":"2002","journal-title":"Epileptic Disord"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/01.WNL.0000103286.47129.F8","article-title":"The impact of pregnancy and childbirth on the metabolism of lamotrigine","volume":"62","author":"Pennell","year":"2004","journal-title":"Neurology"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine","volume":"23","author":"Chan","year":"2001","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:07:16Z","timestamp":1748970436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001205","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"2023-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}